IP Library Granted Patent US 10,809,270
Granted Patent B2
US 10,809,270 · App. 15/578,596 · Granted Oct 20, 2020

Methods for screening for fetal trisomies

Inventors: Enzo Ranieri (Woodville, AU); Steven Ramsay (Viewbank, AU); Peter Charles Kinmont Sharp (Myrtle Bank, AU); Janice Fletcher (Medindie, AU)
Assignee: AUSHEALTH CORPORATE PTY LTD
G01N33/689G01N33/483G01N33/6848G01N33/92G16H10/40G01N2800/387
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,809,270
App. No.
15/578,596
Granted
Oct 20, 2020
Kind
B2
Abstract

The present disclosure relates to methods for screening and identifying a fetal trisomy. Certain embodiments of the present disclosure provide a method of screening for a fetal trisomy in a pregnant female subject. The method comprises detecting one or more lipid markers from the subject, wherein the one or more markers is indicative of the risk of a fetal trisomy in the subject, and determining the risk of a fetal trisomy in the pregnant female subject on the basis of the one or more lipid markers detected.

Claims (19)

1. A method of screening for a fetal trisomy in a pregnant female subject, the method comprising:

exposing a serum sample obtained from the subject in the first trimester of pregnancy to one or more organic solvents and extracting lipids from the sample;

measuring the level of specific lipids in the extracted lipids by mass spectrographic analysis;

using a computer processor comprising instructions that when executed by the processor cause the processor to compare data associated with the level of the specific lipids with data associated with the level of lipids known to be indicative of the risk of a fetal trisomy, the data associated with the level of lipids known to be indicative of the risk of a fetal trisomy being held in computer readable memory; and

determining the risk of a fetal trisomy in the subject on the basis of the risk determined by the computer processor.

2. The method according to claim 1 , wherein the subject is determined to have an increased risk of a fetal trisomy, a low or normal risk of a fetal trisomy, and/or the presence or absence of a fetal trisomy.

3. The method according to claim 1 , wherein the fetal trisomy comprises trisomy 21.

4. The method according to claim 1 , wherein the method comprises determination of the mass of the specific lipids and/or one or more fragments and/or adducts of the specific lipids.

5. The method according to claim 1 , wherein the specific lipids comprise one or more of a phoshopholipid, a glycerolipid, a glycerophospholipid, a sphingolipid, a ceramide, a sterol, a glycosphingolipid, a dolicol, a lysolipid, a fatty acid, a triacylglyceride, a diacylglycerides, a monacylglycerides, an isoprenoid, a prostanoid, an eicosanoid, a sterol derivatives, a prenol lipid, a saccharolipid, a saturated fatty acid, a long chain saturated fatty acid, an unsaturated fatty acid, a polyunsaturated fatty acid, a long chain polyunsaturated fatty acid, a cholesterol and isomers thereof, a dehydrocholesterol and isomers thereof, a cholesterol esters and isomers thereof, a dehydrocholesterol esters and isomers thereof, a lyso derivative of any of the aforementioned lipid markers, and/or a fragment of any of the aforementioned lipid markers.

6. The method according to claim 1 , wherein one or more of the specific lipids comprise a lipid with one or more ions with the following assigned m/z: 703.5580, 369.3491, 367.3312, 680.5953, 687.5651, 445.3648, 445.3633, 727.5567, 429.3706, 1202.3250, 431.3875, 429.3726, 844.6007, 688.5950, 890.7703, 1276.3440, 711.5619, 1128.3140, 670.6080, and/or one or more of the aforementioned lipid markers with a mass tolerance of +/−20 ppm, and/or a substantially similar m/z.

7. The method according to claim 1 , wherein one or more specific lipids comprise a lipid with one or more ions with the following assigned m/z: 340.3576, 355.2511, 363.2531, 390.7783, 399.3453, 404.7929, 407.2269, 408.3136, 427.3771, 429.2121, 447.3448, 447.3460, 461.3620, 469.3597, 471.4063, 473.3184; 478.3545, 481.3239; 489.4134, 506.4412, 530.5135, 544.5071, 551.5172, 555.4646, 558.5448, 568.4784, 579.4305, 603.4949, 604.5660, 607.5640, 618.5444, 626.4976, 640.5345, 640.5699, 647.5577, 676.4879, 684.5594, 700.5542, 728.5875, 740.5176, 744.5807, 772.6135, 780.5458, 788.6118, 798.5637, 817.5510, 816.6401, 820.5947, 826.5947, 832.6303, 834.5978, 850.5523, 860.6632, 864.5363, 876.6591, 902.5855, 904.6889, 904.6932, 920.6888, 928.5873, 948.7143, 964.7115, 992.7408, 1008.7339, 1036.7696, 1052.7680, 1078.9686, 670.6080, and/or one or more of the aforementioned lipid markers with a mass tolerance of +/−20 ppm, and/or a substantially similar m/z.

8. The method according to claim 1 , wherein the method comprises transferring the data associated with the levels of the specific lipids over the internet to the computer processor.

9. The method according to claim 1 , wherein the method is used to identify the presence or absence of a fetal trisomy, to identify a fetal trisomy in the subject, to exclude the presence of a fetal trisomy in the subject, to identify an increased risk of a fetal trisomy, and/or to identify a low or normal risk of a fetal trisomy.

10. A method of determining the risk of a pregnant female subject carrying a fetus with a trisomy, the method comprising:

exposing a serum sample obtained from the subject in the first trimester of pregnancy to one or more organic solvents and extracting lipids from the sample;

measuring the level of specific lipids in the extracted lipids by mass spectrographic analysis;

using a computer processor comprising instructions that when executed by the processor cause the processor to compare data associated with the level of the specific lipids with data associated with the level of lipids known to be indicative of the risk of a fetal trisomy, the data associated with the level of lipids known to be indicative of the risk of a fetal trisomy being held in computer readable memory;

and

determining the risk of the subject carrying a fetus with a trisomy on the basis of the risk determined by the computer processor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2020
From: RANIERI, ENZO; FLETCHER, JANICE; SHARP, PETER; RAMSAY, STEVEN
To: AUSHEALTH CORPORATE PTY LTD
Reel/Frame 053026/0231 →
CHANGE OF NAME Recorded Oct 24, 2018
From: MEDVET SCIENCE PTY. LTD.
To: AUSHEALTH CORPORATE PTY LTD
Reel/Frame 047302/0930 →
Priority Claims (2)
AU 2015902036 · Jun 2, 2015 · national
WO PCT/AU2015/050823 · Dec 21, 2015 · international
Continuity (1)
Related Publication 20180156812A1 · Jun 7, 2018